| Target Price | $107.10 |
| Price | $102.98 |
| Potential |
4.00%
register free of charge
|
| Number of Estimates | 27 |
|
27 Analysts have issued a price target Guardant Health, Inc. 2026 .
The average Guardant Health, Inc. target price is $107.10.
This is
4.00%
register free of charge
$162.75
58.04%
register free of charge
$48.69
52.72%
register free of charge
|
|
| A rating was issued by 33 analysts: 30 Analysts recommend Guardant Health, Inc. to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Guardant Health, Inc. stock has an average upside potential 2026 of
4.00%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 739.02 | 997.66 |
| 31.04% | 35.00% | |
| EBITDA Margin | -54.29% | -21.93% |
| 41.33% | 59.61% | |
| Net Margin | -59.05% | -29.53% |
| 30.55% | 49.99% |
28 Analysts have issued a sales forecast Guardant Health, Inc. 2025 . The average Guardant Health, Inc. sales estimate is
This results in the following potential growth metrics:
25 Analysts have issued an Guardant Health, Inc. EBITDA forecast 2025. The average Guardant Health, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
28 Guardant Health, Inc. Analysts have issued a net profit forecast 2025. The average Guardant Health, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.56 | -2.36 |
| 16.82% | 33.71% | |
| P/E | negative | |
| EV/Sales | 13.89 |
28 Analysts have issued a Guardant Health, Inc. forecast for earnings per share. The average Guardant Health, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Guardant Health, Inc....
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Dec 22 2025 |
| Mizuho |
Locked
➜
Locked
|
Locked | Dec 17 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Dec 15 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Dec 15 2025 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Dec 15 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Dec 15 2025 |
| BTIG |
Locked
➜
Locked
|
Locked | Dec 12 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Dec 22 2025 |
|
Locked
Mizuho:
Locked
➜
Locked
|
Dec 17 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Dec 15 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Dec 15 2025 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Dec 15 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Dec 15 2025 |
|
Locked
BTIG:
Locked
➜
Locked
|
Dec 12 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


